Designates Xylazine as a schedule III depressant

This bill adds Xylazine (a veterinary sedative sometimes misused in human drug markets) to New York State's Schedule III list of controlled substances under public health law. Schedule III classification means Xylazine will now be regulated similarly to drugs like anabolic steroids, requiring prescriptions for medical use and imposing stricter controls on distribution. The law directly affects healthcare providers, pharmacies, and law enforcement by establishing new legal requirements for handling Xylazine. It takes effect 90 days after enactment, following its referral to the Health committee on February 21, 2025.